Nakayama M, Michels AW. Using the T Cell Receptor as a Biomarker in Type 1 Diabetes. Front Immunol. 2021 Nov 17;12:777788.
Mitchell AM, Alkanani AA, McDaniel KA, Pyle L, Waugh K, Steck AK, Nakayama M, Yu L, Gottlieb PA, Rewers MJ, Michels AW. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2019129118.
Mitchell AM, Michels AW. T cell receptor sequencing in autoimmunity. J Life Sci (Westlake Village). 2020 Dec;2(4):38-58.
Simmons KM, Mitchell AM, Alkanani AA, McDaniel KA, Baschal EE, Armstrong T, Pyle L, Yu L, Michels AW. Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-DQB1*06:02. Diabetes. 2020 Aug;69(8):1763-1769.
Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 Sep;36(9):1075-1081.
Akturk HK, Michels AW. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Mar 22;378(12):1163-4.
Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 May 1;128(5):1888-1902.
Nakayama M, McDaniel K, Fitzgerald-Miller L, Kiekhaefer C, Snell-Bergeon JK, Davidson HW, Rewers M, Yu L, Gottlieb P, Kappler JW, Michels A. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4429-34.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4;383(9911):69-82.
Mitchell AM, Alkanani AA, McDaniel KA, Pyle L, Waugh K, Steck AK, Nakayama M, Yu L, Gottlieb PA, Rewers MJ, Michels AW. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2019129118.
Mitchell AM, Michels AW. T cell receptor sequencing in autoimmunity. J Life Sci (Westlake Village). 2020 Dec;2(4):38-58.
Simmons KM, Mitchell AM, Alkanani AA, McDaniel KA, Baschal EE, Armstrong T, Pyle L, Yu L, Michels AW. Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-DQB1*06:02. Diabetes. 2020 Aug;69(8):1763-1769.
Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 Sep;36(9):1075-1081.
Akturk HK, Michels AW. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Mar 22;378(12):1163-4.
Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018 May 1;128(5):1888-1902.
Nakayama M, McDaniel K, Fitzgerald-Miller L, Kiekhaefer C, Snell-Bergeon JK, Davidson HW, Rewers M, Yu L, Gottlieb P, Kappler JW, Michels A. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4429-34.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4;383(9911):69-82.
